1. Home
  2. HKIT vs RFL Comparison

HKIT vs RFL Comparison

Compare HKIT & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HKIT

Hitek Global Inc.

N/A

Current Price

$1.00

Market Cap

25.2M

Sector

Technology

ML Signal

N/A

Logo Rafael Holdings Inc. Class B

RFL

Rafael Holdings Inc. Class B

HOLD

Current Price

$1.34

Market Cap

61.1M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
HKIT
RFL
Founded
1996
2017
Country
China
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Real Estate
Sector
Technology
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
25.2M
61.1M
IPO Year
2018
2017

Fundamental Metrics

Financial Performance
Metric
HKIT
RFL
Price
$1.00
$1.34
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
67.6K
92.9K
Earning Date
01-01-0001
03-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
28.28
EPS
N/A
N/A
Revenue
N/A
$917,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
43.96
52 Week Low
$0.53
$1.12
52 Week High
$4.21
$3.19

Technical Indicators

Market Signals
Indicator
HKIT
RFL
Relative Strength Index (RSI) 29.71 48.08
Support Level $0.53 $1.15
Resistance Level $1.44 $1.38
Average True Range (ATR) 0.19 0.12
MACD -0.06 -0.00
Stochastic Oscillator 33.19 30.00

Price Performance

Historical Comparison
HKIT
RFL

About HKIT Hitek Global Inc.

Hitek Global Inc is a provider of information technology consulting and solutions services. The company has two lines of businesses such as services to small and medium businesses, which consist of Anti-Counterfeiting Tax Control System tax devices, including Golden Tax Disk and printers, ACTCS services, and IT services; and services to large businesses, which include hardware sales and software sales. It generates revenues from hardware sales, software sales, IT services, and tax devices and services.

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.

Share on Social Networks: